Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Congratulations to Sir Dave Stuart, FRS FMedSci, NDM’s Professor of Structural Biology, knighted for services to medical research and the scientific community.

Professor Sir Dave Stuart

Dave is the Founder and Director of the Division of Structural Biology (STRUBI) and Oxford Centre for EM imaging of Infectious Particles (OPIC) and Life Sciences’ Director at the Diamond Light Source. His work ranges across virus-receptor interactions, basic puzzles of virus assembly and studying virus evolution. He has made numerous contributions to the understanding of the structure of viruses, structural vaccinology and anti-viral drug discovery. 

Over the last year, he has led a huge collaborative effort between Diamond, Rosalind Franklin Institute and the University of Oxford studying the structures of SARS-Cov-2 protein structures, and particularly the interaction of the virus’ Spike receptor protein with patient-derived antibodies. This knowledge is being used in anti-COVID19 drug development and tracking and evaluating the significance of new variants. All this work draws heavily on national and international collaborations with academic and industrial partners. Dave has also helped to develop and establish the high-throughput anti-COVID19 antibody screening platform in NDM, which is used by the Office of National Statistics to screen the UK population.

Similar stories

Royal Society Africa Prize 2021 awarded to George Warimwe

The Royal Society Africa Prize 2021 is awarded to Professor George Warimwe for his work on zoonoses vaccine development, capacity building in Africa, and his innovative research proposal. This Prize recognises research scientists based in Africa who are making an innovative contribution to the sciences.

African trial of novel HIV vaccine candidate starts

The Globally Relevant AIDS Vaccine Europe-Africa Trials Partnership (GREAT) – of which the University of Oxford is a lead partner – announced today the start of vaccinations in a Phase I clinical trial of a novel HIV vaccine candidate.

Daily contact COVID-19 testing for students effective at controlling transmission in schools

A study by the University of Oxford has found that daily testing of secondary school students who were in contact with someone with COVID-19 was just as effective in controlling school transmission as the current 10-day contact isolation policy.

How did people in Europe and SE Asia experience the first COVID-19 wave?

An international team, led by Phaik Yeong Cheah, conducted an anonymous online survey from May-June 2020, asking 5,058 people in Thailand, Malaysia, United Kingdom, Italy and Slovenia to share their experiences. Anne Osterrieder and colleagues report the unequal impacts of public health measures, and the prevalence of ‘fake news’.

T-cell ‘training grounds’ behind robust immune system response seen in adenovirus vaccines

Adenovirus vaccine vectors, such as the ChAdOx1 nCov-19 construct which has risen to prominence as a major vaccine for COVID-19, may generate robust long-term immune system responses, according to scientists from the Universities of Oxford and the Cantonal Hospital St.Gallen, Switzerland

HIV vaccine trial starts at Oxford

NDM's Jenner Institute today started vaccinations of a novel HIV vaccine candidate as part of a Phase I clinical trial in the UK.